Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Díaz-Rubio E. Aranda E, et al. Ann Oncol. 2012 Jul;23(7):1919-25. doi: 10.1093/annonc/mdr560. Epub 2011 Dec 9. Ann Oncol. 2012. PMID: 22156621 Free article. Clinical Trial.
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.
Aranda E, Carrato A, Cervantes A, Sastre J, Gómez MA, Abad A, Masutti B, Ribera F, Marcuello E, Pronk L, Balcells M, Díaz-Rubio E; Grupo Español de Traitamiento de Tumores Digestivos. Aranda E, et al. Ann Oncol. 2004 Apr;15(4):559-67. doi: 10.1093/annonc/mdh158. Ann Oncol. 2004. PMID: 15033659 Free article. Clinical Trial.
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E, Valladares M, Martinez-Villacampa M, Benavides M, Gomez A, Massutti B, Marcuello E, Constenla M, Cámara JC, Carrato A, Dueñas R, Reboredo M, Navarro M, Díaz-Rubio E. Aranda E, et al. Ann Oncol. 2009 Feb;20(2):251-7. doi: 10.1093/annonc/mdn557. Epub 2008 Aug 20. Ann Oncol. 2009. PMID: 18718892 Free article. Clinical Trial.
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.
Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, Grávalos C, Escudero P, Vera R, Aranda E, García-Alfonso P, Gallego-Plazas J, Lopez C, Pericay C, Arrivi A, Vicente P, Ballesteros P, Elez E, López-Ladrón A, Díaz-Rubio E. Sotelo MJ, et al. Among authors: aranda e. Ann Oncol. 2015 Mar;26(3):535-41. doi: 10.1093/annonc/mdu568. Epub 2014 Dec 15. Ann Oncol. 2015. PMID: 25515656 Free article.
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Abad A, et al. Among authors: aranda e. Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737. Ann Oncol. 2018. PMID: 29145602 Free article. Clinical Trial.
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C. Vidal J, et al. Among authors: aranda e. Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005. Ann Oncol. 2019. PMID: 30689692 Free article.
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont MJ, Alcaide J, Gómez A, López R, Manzano JL, Méndez Ureña M, Sastre J, Rivera F, Grávalos C, García T, Martín-Valadés JI, Falcó E, Navalón M, González Flores E, Ma García Tapiador A, Ma López Muñoz A, Barrajón E, Reboredo M, García Teijido P, Viudez A, Cárdenas N, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Aranda E, et al. Eur J Cancer. 2018 Sep;101:263-272. doi: 10.1016/j.ejca.2018.06.024. Epub 2018 Jul 24. Eur J Cancer. 2018. PMID: 30054049 Clinical Trial.
Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.).
Díaz-Rubio E, Jimeno J, Aranda E, Massuti B, Camps C, Cervantes A, Dorta J, Cruz Hernández JJ, Dominguez S, Anton A, et al. Díaz-Rubio E, et al. Among authors: aranda e. Ann Oncol. 1992 Dec;3(10):861-3. doi: 10.1093/oxfordjournals.annonc.a058113. Ann Oncol. 1992. PMID: 1286050 Free article. Clinical Trial.
Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Aranda E, Cervantes A, Carrato A, Fernández-Martos C, Antón-Torres A, Massutí T, Barneto I, García-Conde J, Barón JM, Díaz-Rubio E. Aranda E, et al. Ann Oncol. 1996 Aug;7(6):581-5. doi: 10.1093/oxfordjournals.annonc.a010674. Ann Oncol. 1996. PMID: 8879371 Free article. Clinical Trial.
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.
Aranda E, Díaz-Rubio E, Cervantes A, Antón-Torres A, Carrato A, Massutí T, Tabernero JM, Sastre J, Trés A, Aparicio J, López-Vega JM, Barneto I, García-Conde J. Aranda E, et al. Ann Oncol. 1998 Jul;9(7):727-31. doi: 10.1023/a:1008282824860. Ann Oncol. 1998. PMID: 9739438 Free article. Clinical Trial.
457 results